

**TABLE 179: NAIVE SVR GENOTYPE 4 NON-CIRRHOTIC WITH PEARL-I STUDY ADDED: ODDS RATIOS, RELATIVE RISKS, AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR 48	1.17 (0.18 to 1.52)	11.24 (–53.32 to 33.61)
SOF24 + RBV24		1.27 (0.89 to 1.47)	17.83 (–7.15 to 30.20)
PAR/RIT12 + OMB12 + RBV12		1.50 (1.34 to 1.56)	32.29 (21.98 to 35.52)
SOF24 + RBV24	SOF12 + RBV12	1.08 (0.76 to 6.43)	6.36 (–21.66 to 67.74)
PAR/RIT12 + OMB12 + RBV12		1.26 (0.96 to 8.29)	20.18 (–3.57 to 84.75)
PAR/RIT12 + OMB12 + RBV12	SOF24 + RBV24	1.17 (0.99 to 1.66)	13.76 (–0.95 to 38.68)
Random effect model	Residual deviance	5.74 vs. 6 data points	
	Deviance information criteria	35.569	
Fixed effect model	Residual deviance	5.672 vs. 6 data points	
	Deviance information criteria	35.413	

Cri = credible interval; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RIT = ritonavir; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus. Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.